Venture Life Group PLC Comment on mouthwash & COVID-19 transmission (9853M)
15 Maggio 2020 - 8:00AM
UK Regulatory
TIDMVLG
RNS Number : 9853M
Venture Life Group PLC
15 May 2020
15 May 2020
VENTURE LIFE GROUP PLC
("Venture Life" "VLG" or the "Group")
Comment re mouthwash study into potential reduction of COVID-19
transmission
Venture Life (AIM: VLG), a leader in developing, manufacturing
and commercialising products for the international self-care
market, notes the research published yesterday in the journal
Function, which supports the idea that using mouthwash should be
considered as a way to reduce transmission of enveloped viruses
such as COVID-19. A link to the research can be found at the bottom
of this announcement.
The study, which was led by Cardiff University's Systems
Immunity Research Institute and was covered widely by media
outlets, is backed by virologists, lipid specialists and healthcare
experts from the universities of Nottingham, Barcelona and
Cambridge's Babraham Institute. The findings made reference to
mouthwashes containing, among other things, cetylpyridinium
chloride (CPC), which is the main ingredient in Venture Life's key
mouthwash brand - Dentyl Dual Action. Dentyl has been in the UK
market for more than 25 years and is widely available, including
both the UK and China. At this stage, there can be no certainty
that mouthwashes containing CPC will be effective in combatting
COVID-19 or indeed that there will be any impact on trading for the
Company. However, the study recommended further research in this
area and this is fully supported by Venture Life and others.
Further detail on Dentyl can be found in the Company's annual
results, which were announced on 9 April 2020.
Lead author of the study, Professor Valerie O'Donnell,
co-director of Cardiff University's Systems Immunity Research
Institute, said "Our review of the literature suggests that
research is needed as a matter or urgency to determine its
potential for use against this new virus".
Jerry Randall, CEO of Venture Life, commented: "The research
findings published yesterday were very interesting and we fully
support the need for more research into whether existing
mouthwashes on the market, such as those containing CPC, as Dentyl
does, could help to slow the transmission of COVID-19. Venture Life
will make every effort to assist in this research."
Link to research paper:
www.academic.oup.com/function/advance-article/doi/10.1093/function/zqaa002/5836301
For further information, please contact:
Venture Life Group PLC +44 (0) 1344 578004
Jerry Randall, Chief Executive Officer
+44 (0) 20 7397
Cenkos Securities plc (Nomad and Broker) 8900
Stephen Keys / Mark Connelly / Cameron MacRitchie
(Corporate Finance)
Russell Kerr / Michael Johnson (Sales)
About Venture Life ( www.venture-life.com )
Venture Life is an international consumer self-care company
focused on developing, manufacturing and commercialising products
for the global self-care market. With operations in the UK, The
Netherlands and Italy, the Group's product portfolio includes some
key products such as the UltraDEX and Dentyl oral care product
ranges, food supplements for maintaining brain function, medical
devices for women's intimate healthcare, fungal infections and
proctology, and dermo-cosmetics for addressing the signs of
ageing.
The products, which are typically recommended by pharmacists or
healthcare practitioners, are available primarily through
pharmacies and grocery multiples. In the UK and The Netherlands
these are supplied direct by the company to retailers, elsewhere
they are supplied by the Group's international distribution
partners.
Through its Development & Manufacturing business in Italy,
Biokosmes, the Group also provides development and manufacturing
services to companies in the medical devices and cosmetic
sectors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCKKQBDDBKBPPD
(END) Dow Jones Newswires
May 15, 2020 02:00 ET (06:00 GMT)
Grafico Azioni Venture Life (LSE:VLG)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Venture Life (LSE:VLG)
Storico
Da Apr 2023 a Apr 2024